Novartis to Buy Anthos Therapeutics From Blackstone

Novartis buys back Anthos Therapeutics for up to $3.1B
Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement of regulatory and sales milestones. The transaction, which could reach $3.1 billion in total value, is expected to close in the early part of 2025.
M&A News: Novartis Seals $3.1B Deal to Acquire Anthos
Novartis (NVS) has sealed a $3.1 billion deal to acquire clinical-stage biopharmaceutical company Anthos Therapeutics. The deal includes an
Novartis buys Blackstone's Anthos for up to $3.1 billion
By Ludwig Burger and Ariane Luthi (Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.
Novartis to buy Anthos Therapeutics for $925 million
Novartis AG agreed to buy US biotech Anthos Therapeutics for as much as $3.1 billion to gain a preventative stroke medicine that could be the first of its kind. The Swiss drugmaker will pay $925 million upfront and as much as $2.
Novartis agrees to acquire Anthos for up to $3.1B
Novartis (NVS) announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held,
Novartis Strikes Up to $3.1 Billion Deal to Buy Anthos Therapeutics
Novartis (NVS) on Tuesday agreed to acquire biopharmaceutical firm Anthos Therapeutics in a deal worth up to $3.1 billion, as the Swiss pharmaceutical giant looks to boost its cardiovascular portfolio.
Is Novartis AG (NVS) the Best Foreign Dividend Stock to Buy According to Analysts?
We recently compiled a list of the 13 Best Foreign Dividend Stocks To Buy According to Analysts. In this article, we are ...
Novartis: Just What The Doctor Ordered
Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...
Hosted on MSN3h
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug ...
UBS downgrades Novartis AG (NOVN) to a Hold
In a report released today, Matthew Weston from UBS downgraded Novartis AG (NOVN – Research Report) to a Hold, with a price target of ...
Benzinga.com3d
Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal
comprising an upfront payment and potential additional milestone payments. Price Action: NVS stock is down 0.31% at $106.52 during the premarket session on last check Tuesday.
Yahoo Finance3d
Is Novartis AG (NVS) The Best Annual Dividend Stock To Buy Now?
In this article, we are going to take a look at where Novartis AG (NYSE:NVS) stands against other best annual dividend stocks to buy now. In 2025, dividends in MSCI Europe are expected to reach a ...
Nasdaq9d
Here's Why Novartis (NVS) is a Strong Value Stock
Novartis’ efforts to strengthen its wide portfolio ... For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% ...
Novartis AG (NVS): Among the Best Foreign Dividend Stocks to Invest In Now
We recently compiled a list of the 10 Best Foreign Stocks With Dividends For Passive Income. In this article, we are going to ...
UBS cuts Novartis stock rating, lowers price target to CHF104
UBS analyst Matthew Weston downgraded Novartis (SIX:NOVN) shares from Buy to Neutral and reduced the price target from CHF111 ...